The Commercial Problem: Evidence Burden is Now an Access Risk
Market access and HEOR (Health Economics & Outcomes Research) teams are under pressure to prepare evidence faster, adapt it across markets, and respond to HTA and payer scrutiny with confidence. The challenge is no longer only dossier preparation. It is decision readiness: knowing which evidence matters, where the gaps are, which assumptions may be challenged, and how quickly teams can convert fragmented evidence into a defensible access strategy.
Evidence burden is now an access risk. Late evidence-gap visibility can weaken launch readiness, payer confidence, and reimbursement strategy.
This pressure is rising as HTA expectations become more coordinated and more demanding. The EU Joint Clinical Assessment process, applicable from January 2025 for new oncology medicines and advanced therapy medicinal products, is a clear signal that evidence planning needs to become more consistent, reusable, and cross-market ready. For Pharma teams, the commercial imperative is simple: reduce manual evidence burden, improve affiliate preparedness, and identify access risks before they become late-stage submission issues.
Where Agentic AI is Entering HTA and Market Access
Teams across HTA and market access are already exploring agentic AI for evidence and market access workflows, particularly in areas where teams handle large evidence volumes and repetitive expert reviews. Teams can use discovery agents to scan publications, clinical trial reports, regulatory documents, prior HTA decisions, and payer-relevant sources. Screening and extraction agents can support SLR workflows by prioritizing records and extracting endpoints, comparators, safety outcomes, quality-of-life measures, utilities, resource-use inputs, and study characteristics.
Analysts can use synthesis agents to compare findings across sources and flag risks such as weak comparator alignment, immature survival data, inconsistent assumptions, missing utility inputs, or limited generalizability. Dossier and response agents can then support evidence table generation, cross-referencing, draft narrative development, and preparation for likely payer questions.
The opportunity is significant, but the risk is equally clear: AI can accelerate the work, but HTA decisions still depend on expert interpretation, traceability, and governance. EMA and WHO guidance both reinforce the need for transparency, accountability, and human oversight when teams apply AI to health and medicines decisions.
What Evalueserve Does Differently: Agentic AI with Evidence Governance
Evalueserve does not position PharmaHTAInsight as a generic document summarization layer or a push-button HTA engine. Many AI tools can summarize documents or extract information from uploaded files. PharmaHTAInsight goes further by connecting specialized agents across the HTA workflow, including evidence discovery, SLR screening, extraction, synthesis, risk assessment, and dossier support - and embedding them within expert-defined evidence logic, source traceability, and validation checkpoints.
At the technical level, the platform combines retrieval-augmented generation, document intelligence, structured extraction, evidence tagging, and workflow orchestration. Evidence discovery agents identify relevant publications, trial documents, regulatory assessments, prior HTA decisions, and payer-relevant sources. Screening and extraction agents capture endpoints, comparators, safety outcomes, quality-of-life measures, resource-use inputs, utilities, and study characteristics with source-level traceability. Synthesis agents compare evidence across sources, flag inconsistencies, identify gaps, and structure outputs into model-ready inputs for HEOR teams. Risk and dossier agents support payer question anticipation, evidence table generation, narrative drafting, and submission-ready cross-referencing.
The difference is how the workflow is governed. Each output is grounded to source, mapped to the evidence logic, and validated through Human-in-the-Lead checkpoints. Domain experts define the PICO logic, review inclusion and exclusion rules, validate extracted data, assess evidence gaps, and approve the final value narrative. This combination of agentic orchestration, HEOR-aware structuring, and expert governance is what makes PharmaHTAInsight different from standalone AI tools focused mainly on summarization or document Q&A.
The difference is not only that AI is used. The difference is how it is controlled. Each output is grounded to source, mapped to the evidence logic, and validated through Human-in-the-Lead checkpoints. Domain experts define PICO logic, configure inclusion and exclusion rules, review extraction quality, validate model-ready inputs, interpret evidence gaps, and approve the final value narrative. The competitive advantage is the combination of agentic orchestration, source-grounded evidence extraction, HEOR-aware structuring, and expert governance.
|
Typical standalone AI tools
|
Pharma HTA Insight approach
|
|---|---|
|
Summarize uploaded documents or answer one-off questions
|
Connects specialized agents across evidence discovery, screening, extraction, synthesis, risk analysis, and dossier support
|
|
Generate narrative outputs with limited workflow context
|
Maps outputs to HTA evidence logic, PICO structure, HEOR requirements, and payer-relevant questions
|
|
Provide answers that may require manual source checking
|
Grounds outputs to source documents with traceability for validation and defensibility
|
|
Extract information in unstructured or semi-structured formats
|
Structures clinical, economic, comparator, endpoint, utility, and resource-use data into reusable HTA/HEOR-ready formats
|
|
Leave quality review largely to the user
|
Embeds Human-in-the-Lead checkpoints for extraction review, assumption validation, and final value narrative approval
|
|
Operate mainly as a technology tool
|
Combines agentic AI with managed services, HTA/HEOR expertise, medical writing support, and market access delivery experience
|
PharmaHTAInsight is not just an AI layer for summarization. It is a governed, expert-led evidence workflow that turns source-grounded outputs into HTA-ready and HEOR-ready decision support.
Internal Validation: What We Learned from AI-Assisted Screening Across Five Therapy Areas
Evalueserve evaluated an AI-assisted evidence-screening workflow across 989 records spanning five disease areas: vitiligo, narcolepsy, immunoglobulin A nephropathy (IgAN), hidradenitis suppurativa (HS), and amyotrophic lateral sclerosis (ALS). The objective was not to automate final inclusion or exclusion decisions, but to understand where AI could improve screening accuracy, consistency, and prioritization and where additional controls were required.
The exercise showed that a single AI screening step may perform differently across therapy areas because of variations in terminology, study design, endpoint reporting, publication patterns, and inclusion criteria. These findings reinforced the need for an agentic setup in which specialized agents perform distinct tasks, such as evidence discovery, relevance screening, extraction, and quality checks, rather than relying on one model to make every decision.
This multi-agent design is intended to improve accuracy by introducing task specialization, cross-agent validation, confidence-based routing, and review of discordant outputs. Records with uncertain or conflicting classifications can be escalated for expert adjudication, while source-linked reasoning allows reviewers to verify why an inclusion or exclusion recommendation was made.
The validation therefore helped shape a more controlled workflow built around indication-specific calibration, threshold tuning, recall monitoring, and mandatory human review. Within PharmaHTAInsight, agentic AI supports faster and more accurate evidence prioritization, while domain experts retain responsibility for approving the final evidence base before it progresses into synthesis, HEOR analysis, or HTA-ready outputs.
AI for scale, experts for judgment, and managed services for repeatable delivery
For pharma teams, the value is practical: faster evidence of readiness, earlier risk visibility, and fewer late-stage surprises. A Human-in-the-Lead workflow can reduce manual review effort, generate structured evidence tables faster, identify comparator and endpoint risks earlier, create reusable evidence assets across markets, and prepare teams more confidently for HTA and payer questions. It can also reduce late-stage rework by surfacing gaps before dossier finalization.
The future of HTA will not be fully automated. It will be expert-led and AI-enabled. Market access and HEOR teams will still decide which evidence matters, which assumptions are defensible, and how the value story should be positioned. PharmaHTAInsight is designed for that future: AI for scale, experts for judgment, and managed services for repeatable delivery. That is how Human-in-the-Lead AI turns evidence overload into market access advantage.
What’s Next?
If your HTA workflows are still reactive and fragmented, the next step is to identify where evidence of work is slowing down market access readiness. PharmaHTAInsight brings together agentic AI, expert governance, and managed services to help teams move from evidence generation to evidence strategy.
The question is no longer whether to use AI in HTA, but how to use it in a way that is scalable, stays accountable, and supports real decisions.
Request an HTA Evidence Readiness Diagnostic to uncover evidence of bottlenecks, assess AI-readiness, and define a practical roadmap for scalable, expert-led HTA support.
